Présidents de session
Radiobiologie: IV. Radiobiologie : Session Invités
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
Radiobiologie: IV. Radiobiologie : Communications Orales
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
Radiobiologie: IV. Radiobiologie : Discussion et Table ronde
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
Most of what we know about the biological effects of radiations comes from studies using external beam radiation. Particularly, the therapeutic efficacies of low linear energy transfer LET radiation (X and γ rays, electrons) and high (LET) particles radiation used in clinic have been extensively investigated. So far, the biological effects of radiation was considered to be strictly dependent...
Radionuclide therapy consists of the selective irradiation of tumour cells deriving from a radiolabelled molecule or device, specifically located at the tumour site. The consequent effect, on both tumours and normal tissues involved, depends not only on the modality of absorbed dose delivery but also on the specific characteristics of the irradiated tissue and of its microenvironment....
In recent years, Targeted Radionuclide Therapy (TRT) is showing exponential increase of applications due to the availability of new receptor directed ligands, metabolic precursors, monoclonal antibodies, and innovative devices - such as microspheres embedded with radionuclides. A variety of radionuclides, emitting nuclear particles with a range of path lengths from nanometres to millimetres,...
Alpha-radiotherapy is an internal radiation therapy based on the use of α-particle emitters. These radionuclides are highly cytotoxic and altogether their characteristics make them of particular interest in the treatment of disseminated cancers, minimal residual disease and micro-metastases. Nowadays there is a growing interest for these α-emitters whose development in the clinic was so far...
Introduction.
Preclinical studies provide detailed information to evaluate the efficacy and safety of a new radiopharmaceuticals for diagnostic and therapeutic applications. In molecular radiotherapy (MRT) it is essential to calculate absorbed doses to the various structures of interest. Uncertainties in external beam radiotherapy are around 2% to 4%. In contrast, dosimetry for MRT suffers...
Abstract en pièce jointe, en format .docx et .pdf (pour plus de facilité de lecture)
Contexte : Les radionucléides émetteurs d’électrons Auger (EEA) sont très attractifs en thérapie ciblée car ils permettent d’irradier spécifiquement les cellules tumorales ciblées tout en épargnant les tissus sains. Cependant, en raison de leur faible parcours (2 à 500 nm pour énergie < 1KeV) dans les tissus biologiques, il est nécessaire de délivrer les EEA à proximité de cibles...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer associated with a poor prognosis. Current treatments, such as chemotherapy and radiotherapy, fail to improve patient survival. This failure can be explained by PDAC high desmoplasia where cancer associated fibroblasts (CAFs) are the main contributor. Indeed, after conventional X-rays radiotherapy (X-RT), CAFs adopt a senescent...
